Yukiko Doi

Yukiko Doi

Auto-generated profile, based on publicly available information

Yukiko Doi

Department of Hematology and Oncology, Osaka University Graduate School of Medicine , Osaka

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 1990 in Biotechnology Letters
Verified
Journal Article
Closed access
PDF file
MKM. Kataoka
M. Kataoka
SSS. Shimizu
S. Shimizu
YDY. Doi
Y. Doi
KSKeiji Sakamoto
Keiji Sakamoto
HYHisatsugu Yamada
Hisatsugu Yamada

15 April 2022 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
TOTakayuki Ozawa
Takayuki Ozawa
KFKentaro Fujii
Kentaro Fujii
TSTakao Sudo
Takao Sudo
YDYukiko Doi
Yukiko Doi
RNRitsuko Nakai
Ritsuko Nakai
Takafumi YokotaTakafumi Yokota
Takafumi Yokota
Epigenetic mechanisms underpin the elaborate activities of essential transcription factors in lymphocyte development. Special AT-rich sequence-binding protein 1 (SATB1) is a chromatin remodeler that orchestrates the spatial and temporal actions of transcription factors. Previous studies have revealed the significance of SATB1 in T cell lineage. However, whether and how SATB1 controls B cell lineage development is yet to be clarified. In this study, we show that SATB1 is an important factor during splenic B cell maturation. By analyzing SATB1/Tomato reporter mice, we determined the dynamic fluctuation of SATB1 expression in the B cell lineage. Although SATB1 expression decreased to minimal levels during B cell differentiation in the bone marrow, it resurged markedly in naive B cells in the spleen. The expression was dramatically downregulated upon Ag-induced activation. Splenic naive B cells were subdivided into two categories, namely SATB1high and SATB1−/low, according to their SATB1 expression levels. SATB1high naive B cells were less susceptible to death and greater proliferative than were SATB1−/low cells during incubation with an anti-IgM Ab. Additionally, SATB1high cells tended to induce the expression of MHC class II, CD86, and CD83. Accordingly, naive B cells from B lineage–specific SATB1 conditional knockout mice were more susceptible to apoptosis than that in the control group upon anti-IgM Ab stimulation in vitro. Furthermore, conditional knockout mice were less capable of producing Ag-specific B cells after immunization. Collectively, our findings suggest that SATB1 expression increases in naive B cells and plays an important role in their survival and maturation. Key Points SATB1 expression increases in naive B cells and decreases upon BCR activation. SATB1 has roles in the growth and maturation of naive B cells upon BCR activation. SATB1 supports the survival of naive B cells by regulating antiapoptotic genes.

15 February 2022 in Leukemia Research Reports
Verified
Journal Article
Open access
TUTomoaki Ueda
Tomoaki Ueda
KFKentaro Fukushima
Kentaro Fukushima
SKShinsuke Kusakabe
Shinsuke Kusakabe
KYKoki Yoshida
Koki Yoshida
MSMakiko Suga
Makiko Suga
NHNaoki Hosen
Naoki Hosen
To overcome the unfavorable outcome of refractory/relapsed (R/R) Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) and conduct allogeneic stem cell transplantation (allo-SCT) safely, we designed a sequential therapy involving a single cycle of Inotuzumab ozogamicin (InO) and Blinatumomab (Blina). Two heavily treated and aged patients with R/R Ph+ALL were treated with the therapy. Both of them achieved complete molecular remission without cytokine release syndrome and underwent allo-SCT without veno-occlusive disease/sinusoidal obstruction syndrome. Although appropriate central nervous system prophylaxis should be added, the InO-Blina sequential therapy is a promising strategy for treating R/R Ph+ALL as a bridging regimen before allo-SCT.

2 December 2021 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
YDYukiko Doi
Yukiko Doi
Takafumi YokotaTakafumi Yokota
Takafumi Yokota
HSHirohiko Shibayama
Hirohiko Shibayama
KMKana Matsumoto
Kana Matsumoto
MKMasako Kurashige
Masako Kurashige
NHNaoki Hosen
Naoki Hosen
Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) is considered a heterogeneous disease. Therefore, patients with this diagnosis manifest various clinical courses and symptoms, and it i...